Research from Xijing Hospital of Digestive Diseases Yields New Study Findings on Xenografts (Platinum drugs upregulate CXCR4 and PD-L1 expression via ROS-dependent pathways, with implications for novel combined treatment in gastric cancer).

Research from Xijing Hospital of Digestive Diseases has revealed that platinum drugs can increase the expression levels of CXCR4 and PD-L1 in gastric cancer. This study suggests that a combined treatment targeting these molecules may hold promise for gastric cancer patients. The findings indicate that cisplatin-induced upregulation of CXCR4 and PD-L1 is dependent on ROS-dependent pathways, offering potential implications for novel therapeutic approaches in gastric cancer. [Extracted from the article]